Study analysis · Nutrire · 2026
Tomato compound lycopene slashed liver fat by 12% and boosted 'good' cholesterol by 53% in rats – but it didn't help them lose a single gram.
Giving rats with metabolic syndrome a tomato extract (lycopene) for 10 weeks lowered blood fats, raised good cholesterol, and reduced liver fat without affecting body weight or blood pressure.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study used rats, not people, to test if a substance from tomatoes can help with liver problems caused by a bad diet. Because it was a carefully controlled experiment where some rats got the tomato stuff and others didn't, we can be pretty sure that the tomato stuff caused changes in the rats' livers. But rats are not humans, so we don't know if the same would happen in people.
What’s the bottom line?
Scientists fed rats a high-sugar and high-fat diet to make them sick with metabolic syndrome (obesity, high blood pressure, fatty liver). Then they gave some rats a tomato extract called lycopene (the red pigment in tomatoes) for 10 weeks. They measured what happened inside the rats' livers.
How strong is this study?
The study was designed well: they randomly put rats into groups and had a control group, which helps make the results trustworthy. However, the study was small (only 6 rats per group) and we don't know if the researchers were 'blinded' (not knowing which rat got what), which could accidentally influence results. So while the study is good, it's not perfect and we need more research to be sure.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
57 / 100
- Randomization+20/20
- Blindingblinding unclear
- Control group+15/15
- Sample size (n=6)+0.6/20
- Follow-up+10/10
100 / 100
23 / 100
- P-values+15/15
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 514 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design cannot establish causation — the findings describe an association, not a cause. This is an animal study (rats), not humans. While the randomized design can establish cause-effect relationships in the rat model, findings cannot be directly extrapolated to humans due to species differences and the preclinical nature of the study.
COI Unknown
Could not determine conflict of interest status
No conflicts of interest or funding information provided in the available text.
The provided text does not include a conflict of interest declaration or funding statement. The study appears to be academic, but without full disclosure, bias potential cannot be assessed.
Key takeaways
- 01
Lycopene lowered liver fat by about 12% and improved blood fats (reduced triglycerides by 19.5%, raised good cholesterol by 52.6%).
- 02
It also fixed the levels of certain amino acids (building blocks of proteins) that were messed up by the bad diet.
- 03
This is a rat study, so we don't know if it works exactly the same in humans.
- 04
But if it does, it suggests that eating tomatoes or taking lycopene supplements might help people with fatty liver disease.
Surprising findings
- Lycopene increased liver levels of branched-chain amino acids (BCAAs) by up to 36%High blood levels of BCAAs are linked to insulin resistance and metabolic syndrome. But here, lycopene raised liver BCAAs, which suggests tissue-specific regulation – the liver was 'starving' for these amino acids.
- Lycopene increased a liver signaling lipid called sphinganine-1-phosphate (S1P) by 22.6%S1P is usually associated with inflammation and cancer progression, but in the liver, it may have protective roles via SphK2 enzyme. This study suggests lycopene activates a beneficial pathway.
- Lycopene did not affect body weight or blood pressure despite improving other metabolic markersMany people assume that improving metabolic health automatically leads to weight loss or lower blood pressure. This study shows that metabolic improvements can occur independently.
Practical takeaways
Consider adding more tomatoes or lycopene-rich foods (tomato paste, cooked tomatoes, watermelon) to your diet to support liver and heart health.
This is an animal study; human trials are needed. Also, the dose used (approximately 57 mg/day for a human) is higher than typical dietary intake (5–10 mg/day).
low confidenceIf you have metabolic syndrome or fatty liver, don't rely on lycopene alone – it didn't affect weight or blood pressure. Use it as part of a comprehensive lifestyle change.
The study didn't test lycopene in combination with other interventions like exercise or calorie restriction.
medium confidenceConsult a doctor before taking high-dose lycopene supplements, especially if on blood pressure medication (though no interaction was found).
Safety of long-term high-dose lycopene supplementation in humans is not well studied.
medium confidenceWhy this study matters
Liver fat reduced by 12%
Rats with diet-induced metabolic syndrome had 11.9% less fat stored in their livers after lycopene supplementation. This suggests lycopene directly protects the liver from fatty buildup.
Fatty liver disease affects about 25% of adults worldwide, and many don't even know they have it. A natural compound from tomatoes could help manage it.
Good cholesterol up 53%, bad fats down 20%
Lycopene raised HDL-cholesterol by 52.6% and lowered triglycerides by 19.5% in rats. These are significant changes in blood lipid profile linked to heart health.
Most people focus on lowering 'bad' cholesterol, but raising 'good' cholesterol is equally important. This study shows a single food compound can do both.
No weight loss, no blood pressure drop
Lycopene did not change body weight, adiposity index, or systolic blood pressure. Its benefits are purely metabolic, not related to fat loss or hypertension.
Many people assume a compound that improves metabolic health will also cause weight loss. This study challenges that assumption.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists fed rats a high-sugar and high-fat diet to make them sick with metabolic syndrome (obesity, high blood pressure, fatty liver). Then they gave some rats a tomato extract called lycopene (the red pigment in tomatoes) for 10 weeks. They measured what happened inside the rats' livers.
Research results
Lycopene lowered liver fat by about 12% and improved blood fats (reduced triglycerides by 19.5%, raised good cholesterol by 52.6%). It also fixed the levels of certain amino acids (building blocks of proteins) that were messed up by the bad diet.
What this means - more context
This is a rat study, so we don't know if it works exactly the same in humans. But if it does, it suggests that eating tomatoes or taking lycopene supplements might help people with fatty liver disease.
To investigate the effects of lycopene supplementation (as tomato oleoresin) on hepatic metabolic alterations in a rat model of diet-induced metabolic syndrome using non-targeted metabolomics.
Tomato oleoresin supplementation (5 mg/kg/day lycopene) in Wistar rats with diet-induced metabolic syndrome reduced plasma triglycerides (19.5%), increased HDL-cholesterol (52.6%), and attenuated hepatic triglyceride accumulation (11.9%). Metabolomic profiling revealed that lycopene partially reversed hepatic metabolic disruptions, notably increasing hepatic levels of branched-chain amino acids (D-leucine +36.4%, L-leucine +29.0%, L-isoleucine +28.4%) and sphinganine-1-phosphate (22.6%). Lycopene did not affect body weight, adiposity index, or systolic blood pressure.
Methods Used
Male Wistar rats (n=6/group) fed a high sugar-fat diet (HSFD) for 20 weeks to induce metabolic syndrome, then supplemented with tomato oleoresin (10 mg/kg/day, equivalent to 5 mg/kg/day lycopene) or vehicle via oral gavage for 10 additional weeks. Hepatic metabolites were analyzed by flow infusion electrospray ionization high-resolution mass spectrometry (FIE-HRMS) with PLS-DA and ANOVA.
Main Finding
Lycopene supplementation (5 mg/kg/day) reduces hepatic steatosis, improves dyslipidemia, and restores hepatic branched-chain amino acid levels in rats with diet-induced metabolic syndrome, suggesting hepatoprotective effects via modulation of amino acid and sphingolipid metabolism.
Confidence Level
Moderate: small sample size (6/group), animal model, exploratory metabolomics without correction for multiple comparisons fully reported, some mechanistic pathways inferred without enzyme measurements.
Study Flags
Red Flags
- •Small sample size (n=6 per group) limits statistical power
- •Only male Wistar rats used, limiting generalizability
- •Metabolomic results not corrected for multiple comparisons (only ANOVA with FDR mentioned but not fully detailed)
Surprising Findings
Lycopene increased liver levels of branched-chain amino acids (BCAAs) by up to 36%
High blood levels of BCAAs are linked to insulin resistance and metabolic syndrome. But here, lycopene raised liver BCAAs, which suggests tissue-specific regulation – the liver was 'starving' for these amino acids.
Practical Takeaways
Consider adding more tomatoes or lycopene-rich foods (tomato paste, cooked tomatoes, watermelon) to your diet to support liver and heart health.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 514 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Animal RCT
Subject
Lower probability
on the GRADE evidence scale
This study used rats, not people, to test if a substance from tomatoes can help with liver problems caused by a bad diet. Because it was a carefully controlled experiment where some rats got the tomato stuff and others didn't, we can be pretty sure that the tomato stuff caused changes in the rats' livers. But rats are not humans, so we don't know if the same would happen in people.
Strengths
- Randomized controlled design
- Control group included
- Pre-specified sample size calculation (power analysis)
Weaknesses
- Animal model limits human applicability
- Blinding of investigators not reported
- Small sample size (n=6 per group) despite power analysis
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists fed rats a high-sugar and high-fat diet to make them sick with metabolic syndrome (obesity, high blood pressure, fatty liver). Then they gave some rats a tomato extract called lycopene (the red pigment in tomatoes) for 10 weeks. They measured what happened inside the rats' livers.
Research results
Lycopene lowered liver fat by about 12% and improved blood fats (reduced triglycerides by 19.5%, raised good cholesterol by 52.6%). It also fixed the levels of certain amino acids (building blocks of proteins) that were messed up by the bad diet.
What this means - more context
This is a rat study, so we don't know if it works exactly the same in humans. But if it does, it suggests that eating tomatoes or taking lycopene supplements might help people with fatty liver disease.
To investigate the effects of lycopene supplementation (as tomato oleoresin) on hepatic metabolic alterations in a rat model of diet-induced metabolic syndrome using non-targeted metabolomics.
Tomato oleoresin supplementation (5 mg/kg/day lycopene) in Wistar rats with diet-induced metabolic syndrome reduced plasma triglycerides (19.5%), increased HDL-cholesterol (52.6%), and attenuated hepatic triglyceride accumulation (11.9%). Metabolomic profiling revealed that lycopene partially reversed hepatic metabolic disruptions, notably increasing hepatic levels of branched-chain amino acids (D-leucine +36.4%, L-leucine +29.0%, L-isoleucine +28.4%) and sphinganine-1-phosphate (22.6%). Lycopene did not affect body weight, adiposity index, or systolic blood pressure.
Methods Used
Male Wistar rats (n=6/group) fed a high sugar-fat diet (HSFD) for 20 weeks to induce metabolic syndrome, then supplemented with tomato oleoresin (10 mg/kg/day, equivalent to 5 mg/kg/day lycopene) or vehicle via oral gavage for 10 additional weeks. Hepatic metabolites were analyzed by flow infusion electrospray ionization high-resolution mass spectrometry (FIE-HRMS) with PLS-DA and ANOVA.
Main Finding
Lycopene supplementation (5 mg/kg/day) reduces hepatic steatosis, improves dyslipidemia, and restores hepatic branched-chain amino acid levels in rats with diet-induced metabolic syndrome, suggesting hepatoprotective effects via modulation of amino acid and sphingolipid metabolism.
Confidence Level
Moderate: small sample size (6/group), animal model, exploratory metabolomics without correction for multiple comparisons fully reported, some mechanistic pathways inferred without enzyme measurements.
Study Flags
Red Flags
- •Small sample size (n=6 per group) limits statistical power
- •Only male Wistar rats used, limiting generalizability
- •Metabolomic results not corrected for multiple comparisons (only ANOVA with FDR mentioned but not fully detailed)
Surprising Findings
Lycopene increased liver levels of branched-chain amino acids (BCAAs) by up to 36%
High blood levels of BCAAs are linked to insulin resistance and metabolic syndrome. But here, lycopene raised liver BCAAs, which suggests tissue-specific regulation – the liver was 'starving' for these amino acids.
Practical Takeaways
Consider adding more tomatoes or lycopene-rich foods (tomato paste, cooked tomatoes, watermelon) to your diet to support liver and heart health.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 514 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Animal RCT
Subject
Lower probability
on the GRADE evidence scale
This study used rats, not people, to test if a substance from tomatoes can help with liver problems caused by a bad diet. Because it was a carefully controlled experiment where some rats got the tomato stuff and others didn't, we can be pretty sure that the tomato stuff caused changes in the rats' livers. But rats are not humans, so we don't know if the same would happen in people.
Strengths
- Randomized controlled design
- Control group included
- Pre-specified sample size calculation (power analysis)
Weaknesses
- Animal model limits human applicability
- Blinding of investigators not reported
- Small sample size (n=6 per group) despite power analysis
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The study was designed well: they randomly put rats into groups and had a control group, which helps make the results trustworthy. However, the study was small (only 6 rats per group) and we don't know if the researchers were 'blinded' (not knowing which rat got what), which could accidentally influence results. So while the study is good, it's not perfect and we need more research to be sure.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
57 / 100
- Randomization+20/20
- Blindingblinding unclear
- Control group+15/15
- Sample size (n=6)+0.6/20
- Follow-up+10/10
100 / 100
23 / 100
- P-values+15/15
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 514 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design cannot establish causation — the findings describe an association, not a cause. This is an animal study (rats), not humans. While the randomized design can establish cause-effect relationships in the rat model, findings cannot be directly extrapolated to humans due to species differences and the preclinical nature of the study.
COI Unknown
Could not determine conflict of interest status
No conflicts of interest or funding information provided in the available text.
The provided text does not include a conflict of interest declaration or funding statement. The study appears to be academic, but without full disclosure, bias potential cannot be assessed.
Standing
Who’s using this study?
The videos and claims on this site that lean on this study, and the researchers who wrote it.
1 video from Physionic cite this study, drawing 1 claim from it.
- Indication only
Weak evidence — fewer than 20 studies, so treat this as a starting point, not a fact.
Evidence